The Rate Of Blood Coagulation Is Determined Genetically.
In an attainment to uncover why some people's blood platelets cluster faster than others, a genetic interpretation has turned up a specific grouping of overactive genes that seems to control the process. On the addition side, platelets are critical for fending off infections and healing wounds. On the down side, they can rush heart disease, heart attacks and stroke, the study authors noted.
The current find regarding the genetic roots driving platelet behavior comes from what is believed to be the largest reassessment of the human genetic code to date, according to co-senior study investigator Dr Lewis Becker, a cardiologist with the Johns Hopkins University School of Medicine. "Our results give us a palpable set of unheard of molecular targets, the proteins produced from these genes, to develop tests that could help us identify subjects more at risk for blood clots and for whom certain blood-thinning drugs may work best or not," Becker said in a Johns Hopkins low-down release.
So "We can even look toward testing new treatments that may scurry up how the body fights infection or recovers from wounds". The study findings were published online June 7 in Nature Genetics.
Showing posts with label platelet. Show all posts
Showing posts with label platelet. Show all posts
Tuesday, 23 May 2017
Monday, 13 March 2017
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing empathy attacks, blood clots or passing than the recognized lower dose in patients who had received artery-opening stents, late research shows. The higher dose - double-barrelled the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to counter to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have gloomy platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the further study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to enquiry lead author Dr Matthew Price, who presented the findings Tuesday at the annual encounter of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to entertain heart patients who don't respond well to Plavix? "It remains variable to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an conspicuous study to have done but the key issues are that a significant proportion of the patients remained with serious platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the amount was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a squiffy reactivity plane is associated with poorer outcomes after angioplasty and/or stenting. But until now, a sharp rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Higher doses of the blood-thinner Plavix were no better at preventing empathy attacks, blood clots or passing than the recognized lower dose in patients who had received artery-opening stents, late research shows. The higher dose - double-barrelled the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to counter to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have gloomy platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the further study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to enquiry lead author Dr Matthew Price, who presented the findings Tuesday at the annual encounter of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to entertain heart patients who don't respond well to Plavix? "It remains variable to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an conspicuous study to have done but the key issues are that a significant proportion of the patients remained with serious platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the amount was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a squiffy reactivity plane is associated with poorer outcomes after angioplasty and/or stenting. But until now, a sharp rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Subscribe to:
Posts (Atom)